Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection - PubMed (original) (raw)

Comparative Study

Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection

P A Marchildon et al. J Clin Microbiol. 1996 May.

Abstract

The diagnostic significance of the serological detection of antibodies to Helicobacter pylori has been established by numerous investigators. Reports of the clinical reliabilities of commercial enzyme immunoassay (EIA) kits available for this purpose vary as a result of the different H. pylori antigen sources and reference methods used. The 13C urea breath test (UBT) has been shown to be an extremely accurate and reliable method of detecting H. pylori infection. We used the 13C urea breath test as the confirmatory method for H. pylori status to evaluate three commercially available EIA kits designed to detect immunoglobulin G antibodies to H. pylori. These kits were the HM-CAP EIA kit (Enteric Products, Inc.), the PYLORI STAT EIA kit (BioWhittaker, Inc.), and the G.A.P. kit (Bio-Rad Laboratories/Biomerica, Inc.). The evaluations were performed in a double-blind manner with samples from 473 clinically characterized patients. This group included patients with symptomatic gastrointestinal disorders as well as nonsymptomatic volunteers. The sensitivities of the kits were as follows: HM-CAP, 98.4%; PYLORI STAT, 99.2%; and G.A.P., 100%. The specificities were as follows: HM-CAP, 96.4%; PYLORI STAT, 90.1%; and G.A.P., 26.0%. Although the HM-CAP and PYLORI STAT kits performed comparably, the G.A.P. test yielded significantly more false-positive results and an unacceptably high number of indeterminate results.

PubMed Disclaimer

Cited by

Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H, Saito T, Nakamura T, Yamao K, Hamajima N, Tajima K. Suzuki T, et al. Epidemiol Infect. 2007 Jan;135(1):171-6. doi: 10.1017/S0950268806006613. Epub 2006 Jun 2. Epidemiol Infect. 2007. PMID: 16740190 Free PMC article.
Aspirin and risk for gastric cancer: a population-based case-control study in Sweden.
Akre K, Ekström AM, Signorello LB, Hansson LE, Nyrén O. Akre K, et al. Br J Cancer. 2001 Apr 6;84(7):965-8. doi: 10.1054/bjoc.2001.1702. Br J Cancer. 2001. PMID: 11286478 Free PMC article.
Relation of Helicobacter pylori infection and lifestyle to the risk of chronic atrophic gastritis: a cross-sectional study in Japan.
Shibata K, Moriyama M, Fukushima T, Une H, Miyazaki M, Yamaguchi N. Shibata K, et al. J Epidemiol. 2002 Mar;12(2):105-11. doi: 10.2188/jea.12.105. J Epidemiol. 2002. PMID: 12033520 Free PMC article.
Diagnosis of Helicobacter pylori infection in children: comparison of a salivary immunoglobulin G antibody test with the [(13)C]urea breath test.
Bode G, Marchildon P, Peacock J, Brenner H, Rothenbacher D. Bode G, et al. Clin Diagn Lab Immunol. 2002 Mar;9(2):493-5. doi: 10.1128/cdli.9.2.493-495.2002. Clin Diagn Lab Immunol. 2002. PMID: 11874901 Free PMC article.
Dietary quercetin intake and risk of gastric cancer: results from a population-based study in Sweden.
Ekström AM, Serafini M, Nyrén O, Wolk A, Bosetti C, Bellocco R. Ekström AM, et al. Ann Oncol. 2011 Feb;22(2):438-43. doi: 10.1093/annonc/mdq390. Epub 2010 Aug 5. Ann Oncol. 2011. PMID: 20688844 Free PMC article.

References

1. Lancet. 1987 May 23;1(8543):1174-7 - PubMed
1. Aliment Pharmacol Ther. 1995;9 Suppl 2:21-31 - PubMed
1. Ann Intern Med. 1988 Jul 1;109(1):11-7 - PubMed
1. Med J Aust. 1988 Dec 5-19;149(11-12):604-9 - PubMed
1. Gastroenterology. 1989 Apr;96(4):1004-8 - PubMed

Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection - PubMed (original) (raw)